Combination of transarterial therapy with sorafenib for hepatocellular carcinoma.

被引：1
|
作者：
Cabrera, R.
Pannu, D. S.
Caridi, J.
Firpi, R.
Soldevila-Pico, C.
Morelli, G.
Clark, V.
George, T. J.
Nelson, D.
机构：
[1] Univ Florida, Coll Med, Gainesville, FL USA
[2] Univ Florida, Gainesville, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e14598
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14598
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A preclinical study on the combination therapy of everolimus and transarterial chemoembolization in hepatocellular carcinoma
    Chow, Ariel K. M.
    Yau, Thomas C. C.
    Ng, Lui
    Chu, Andrew C. Y.
    Law, Wai-Lun
    Poon, Ronnie T. P.
    Pang, Roberta W. C.
    AMERICAN JOURNAL OF CANCER RESEARCH, 2015, 5 (08): : 2376 - 2386
  • [32] EASL- and mRECIST-Evaluated Responses to Combination Therapy of Sorafenib with Transarterial Chemoembolization Predict Survival in Patients with Hepatocellular Carcinoma
    Liu, Lei
    Wang, Weijuan
    Chen, Hui
    Zhao, Yan
    Bai, Wei
    Yin, Zhanxin
    He, Chuangye
    Jia, Jia
    Yang, Man
    Xia, Jielai
    Fan, Daiming
    Han, Guohong
    CLINICAL CANCER RESEARCH, 2014, 20 (06) : 1623 - 1631
  • [33] Combination therapy of sorafenib and drug-eluting bead transarterial chemoembolization for advanced hepatocellular carcinoma with and without hepatic arteriovenous shunt
    Chen, Pin-Ko
    Chiu, Sung-Hua
    Tsai, Ming-Ting
    Chang, Kai-Hsiang
    Chang, Wei-Chou
    Lin, Hsuan-Hwai
    Lo, Cheng-Hsiang
    Huang, Guo-Shu
    Chang, Ping-Ying
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2022, 85 (04) : 491 - 499
  • [34] LXR agonism and Sorafenib treatment as novel combination therapy for hepatocellular carcinoma
    Preziosi, Morgan E.
    Zahm, Adam M.
    Kaestner, Klaus H.
    Wangensteen, Kirk J.
    FASEB JOURNAL, 2019, 33
  • [35] Concurrent versus Sequential Sorafenib Therapy in Combination with Radiation for Hepatocellular Carcinoma
    Wild, Aaron T.
    Gandhi, Nishant
    Chettiar, Sivarajan T.
    Aziz, Khaled
    Gajula, Rajendra P.
    Williams, Russell D.
    Kumar, Rachit
    Taparra, Kekoa
    Zeng, Jing
    Cades, Jessica A.
    Velarde, Esteban
    Menon, Siddharth
    Geschwind, Jean F.
    Cosgrove, David
    Pawlik, Timothy M.
    Maitra, Anirban
    Wong, John
    Hales, Russell K.
    Torbenson, Michael S.
    Herman, Joseph M.
    Tran, Phuoc T.
    PLOS ONE, 2013, 8 (06):
  • [36] TACE plus sorafenib for the treatment of advanced hepatocellular carcinoma.
    Palwe, Vijay Sukhdeo
    Nagarkar, Rajnish Vasant
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] Clinical predictors of response to sorafenib in patients with hepatocellular carcinoma.
    Marinelli, Sara
    Granito, Alessandro
    Terzi, Eleonora
    Leoni, Simona
    Piscaglia, Fabio
    Venerandi, Laura
    Bolondi, Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Safety of drug-eluting beads transarterial chemoembolization under the combination therapy with immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
    Chiu, Sung-Hua
    Chang, Wei-Chou
    Hsieh, Chung-Bao
    Feng, An-Chieh
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 556 - 556
  • [39] Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
    Huang Yong-hui
    Chen Wei
    Li Jia-ping
    Chen Bin
    Yang Jian-yong
    CHINESE MEDICAL JOURNAL, 2013, 126 (02) : 385 - 386
  • [40] PHASE II STUDY OF THE CONCURRENT COMBINATION OF CONVENTIONAL TRANSARTERIAL CHEMOEMBOLIZATION AND SORAFENIB FOR PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Park, Joong-Won
    Kim, Hwi Young
    Ahn, Sang Bu
    Choi, Joon-Il
    Woo, Sang Myung
    Kim, Hyun-Beom
    KoH, Young Hwan
    Nam, Byung Ho
    HEPATOLOGY, 2011, 54 : 1443A - 1443A
12345